On invitation of the Novo Nordisck Foundation, an interactive story on personalized healthcare, biomarkers and innovation in proteomics for a group of enthousiastic young scientists.
2016 09-12 Europe Biobanking Week, Vienna, Alain van GoolAlain van Gool
Opening keynote of the Europe Biobanking Week, outlining reasons why we should join forces in validation and development of biomarker in personalized medicinand health.
2016 08-22 Radboud Grand Round, Nijmegen, Alain van GoolAlain van Gool
Interactive lecture with a large group of healthcare professionals, scientists and patients to illustrate developments in personalized healthcare and the role of technology to support science, innovations and medical impact. (slides in English)
2016 09-21 symposium Opening the BBMRI genomics infrastructure in The Netherl...Alain van Gool
Keynote lecture for the BBMRI genomics community at this BBMRI symposium, outlining my perspective on personalized medicine and health, and the various activities within The Netherlands to shape the healthRI.
2016 11-01 Biomarker Agora, Copenhagen, Alain van GoolAlain van Gool
This document discusses the development and validation of clinical molecular biomarkers. It begins with an example of how the B-RAFV600E mutation in melanoma can be used for personalized medicine approaches. It then describes efforts to validate interleukin-8 (IL-8) as a biomarker for ERK pathway inhibition, which involved extensive biomarker profiling and validation studies but ultimately found the data to be irreproducible. The document emphasizes the need for improved biomarker validation practices and increased collaboration to address gaps between biomarker discovery and clinical application.
2016-02-18 Innovation for Health 2016 conference, Rotterdam Alain van GoolAlain van Gool
Lecture on personalized healthcare in a great session at the Innovation for Health 2016 conference, discussing opportunities and challenges with 800 scientists, enterpreneurs and care professionals.
Lecture on biomarkers (principles, potentials, pitfalls) for 200 pharmaceutical professionals as part of the IMI Pharma Train course organised by the European Center for Pharmaceutical Medicine
Great evening with the Rotary Oss where I got the opportunity to discuss current and future prospects in personalized healthcare with a good group of interested people.
2016 09-12 Europe Biobanking Week, Vienna, Alain van GoolAlain van Gool
Opening keynote of the Europe Biobanking Week, outlining reasons why we should join forces in validation and development of biomarker in personalized medicinand health.
2016 08-22 Radboud Grand Round, Nijmegen, Alain van GoolAlain van Gool
Interactive lecture with a large group of healthcare professionals, scientists and patients to illustrate developments in personalized healthcare and the role of technology to support science, innovations and medical impact. (slides in English)
2016 09-21 symposium Opening the BBMRI genomics infrastructure in The Netherl...Alain van Gool
Keynote lecture for the BBMRI genomics community at this BBMRI symposium, outlining my perspective on personalized medicine and health, and the various activities within The Netherlands to shape the healthRI.
2016 11-01 Biomarker Agora, Copenhagen, Alain van GoolAlain van Gool
This document discusses the development and validation of clinical molecular biomarkers. It begins with an example of how the B-RAFV600E mutation in melanoma can be used for personalized medicine approaches. It then describes efforts to validate interleukin-8 (IL-8) as a biomarker for ERK pathway inhibition, which involved extensive biomarker profiling and validation studies but ultimately found the data to be irreproducible. The document emphasizes the need for improved biomarker validation practices and increased collaboration to address gaps between biomarker discovery and clinical application.
2016-02-18 Innovation for Health 2016 conference, Rotterdam Alain van GoolAlain van Gool
Lecture on personalized healthcare in a great session at the Innovation for Health 2016 conference, discussing opportunities and challenges with 800 scientists, enterpreneurs and care professionals.
Lecture on biomarkers (principles, potentials, pitfalls) for 200 pharmaceutical professionals as part of the IMI Pharma Train course organised by the European Center for Pharmaceutical Medicine
Great evening with the Rotary Oss where I got the opportunity to discuss current and future prospects in personalized healthcare with a good group of interested people.
2016 04-21 Association of Dutch Producers of Children and Diet Nutrition (VNF...Alain van Gool
Keynote lecture at the 55-year lustrum conference of the Association of Dutch Producers of Children and Diet Nutrition (VNFKD) to reflect on the use of (specialized) nutrition in personalized healthcare.
2020 02-10 European Center Pharmaceutical Medicine course - biomarkers, Basel...Alain van Gool
This document discusses biomarkers and personalized healthcare. It begins with an overview of biomarkers in the pharmaceutical industry and how they are used from drug discovery through clinical trials. It then discusses biomarkers in academic research and healthcare, and how emerging digital biomarkers could enable personalized health monitoring. The presentation identifies some translational innovation gaps, and concludes with an outlook on how biomarkers and multi-omics approaches will continue to advance personalized diagnosis and therapies.
2020 08-28 SensUs Event 2020 keynote, Eindhoven, Alain van GoolAlain van Gool
Closing keynote for international students participating in the SensUs Event 2020, where they designed and created a novel sensor for drug level monitoring in epilepsy treatment. Lecture outlined innovations in biomarkers in personalized health(care).
2020 09-07 European Center Pharmaceutical Medicine course Biomarkers, Basel, ...Alain van Gool
Tutorial lecture on biomarkers for pharmaceutical industry R&D professionals, outlining status, potential and challenges of biomarkers in pharma, clinic and society.
2021 03-25 11th World Clinical Biomarkers & Companion Diagnostics, Alain van ...Alain van Gool
Closing keynote of a 3-day conference on clinical biomarkers and companion diagnostics, organised by Hanson Wade, outlining the power of omics approaches in healthcare and translation of inovations to impact.
2019 06-19 Dutch association for clinical chemistry and laboratory medicine -...Alain van Gool
Sharing my views on how X-omics biomarker analyses through next gen sequencing and mass spectrometry will change the landscape of diagnostics and clinical chemistry in the near future.
2019 10-14 2nd Int Congress on Precision Medicine, Munich, Alain van GoolAlain van Gool
Opening lecture at the 2nd International Congress on Precision Medicine in Munich, outlining progress in omics-based biomarkers for rare diseases, biomarker innovation gaps and multi-partner initiatives to bridge those gaps to applications. Also reviewed the highlights of our recently published Handbook of Biomarkers and Precision Medicine.
2021 06-14 EATRIS-Plus summer school, Alain van GoolAlain van Gool
Introductory lecture for the 100 participant summer school of the EATRIS-Plus project, outlining personalized medicine, biomarker and multi-omics strategies and use cases.
2018 11-26 KNAW-AcTI symposium Personalized Health, Amsterdam, Alain van GoolAlain van Gool
Lecture at a citizen discussion evening, reviewing the promises and (ethical) considerations of technology developments to support personalized health, organised by the Royal Academy of Sciences and the Netherlands Academy of Technology and Innovation.
ClinicalCodes.org: An online repository of clinical code lists for primary ca...David Springate
This document discusses ClinicalCodes.org, an online repository for clinical code lists used in primary care database research. It outlines issues with a lack of published code lists, such as inability to validate or replicate studies and difficulty comparing studies over time as condition definitions change. ClinicalCodes.org aims to address these issues by providing a central location for researchers to upload, download, and archive code lists. This would improve research quality and allow other researchers to build upon previous work in a standardized way. Motivations for researchers to upload their code lists include validation of their work, increased citations, and a requirement by journals and funders for transparent and accessible code lists.
2017 09-20 HUPO2017, Dublin, Alain van Gool withsupplAlain van Gool
Keynote lecture at the HUPO 2017 in Dublin, focussing on our innovations in translational omics for applications in our personalized healthcare at Radboudumc.
2018 03-01 International Conference on Perspectives in Precision Medicine, Co...Alain van Gool
This keynote lecture reviews the historical and ongoing investments in public-private partnerships related to precision medicine and the related technological infrastructures. It served as example to the Danish community how translational biomarkers in precision medicine can be organised, as basis for further collaboration between Denmark and Netherlands.
2017 02-22 Oxford Global Biomarker Congress, Manchester, Alain van GoolAlain van Gool
Outline of various technology infrastructures (in Radboudumc, Netherlands, European) aiming at filing innovation gaps in personalized medicine and health research.
Clinicians and microbiologists should follow proper procedures for collecting and handling wound swab specimens to obtain accurate microbiology results. Specimens should be collected prior to cleaning or antimicrobial treatment, using sterile collection methods. Swabs should be placed in transport media and containers sealed and transported promptly to the laboratory. Microbiologists should not receive specimens for acid-fast bacilli on swabs, as pus or tissue is preferred. Clinicians need to understand that positive cultures do not necessarily indicate infection, as opportunistic organisms may colonize wounds, and microbiology results depend on the quality of the specimen collected.
Two-thirds of survey respondents reported using a subscription video on demand (SVOD) service. Nearly half use their SVOD service as much as or more than their pay TV service. Three-quarters of SVOD users experience buffering and slow stream starts, and nearly 20% consider technical problems serious enough to cancel their service. Password sharing is common, primarily between family members, though concerns about its impact are likely overblown according to the research. Consumers expect a high-quality, premium viewing experience from SVOD services.
A empresa de tecnologia anunciou um novo smartphone com câmera aprimorada, maior tela e bateria de longa duração. O dispositivo também possui processador mais rápido e armazenamento expansível. O novo modelo será lançado em outubro por um preço inicial de US$799.
2016 04-21 Association of Dutch Producers of Children and Diet Nutrition (VNF...Alain van Gool
Keynote lecture at the 55-year lustrum conference of the Association of Dutch Producers of Children and Diet Nutrition (VNFKD) to reflect on the use of (specialized) nutrition in personalized healthcare.
2020 02-10 European Center Pharmaceutical Medicine course - biomarkers, Basel...Alain van Gool
This document discusses biomarkers and personalized healthcare. It begins with an overview of biomarkers in the pharmaceutical industry and how they are used from drug discovery through clinical trials. It then discusses biomarkers in academic research and healthcare, and how emerging digital biomarkers could enable personalized health monitoring. The presentation identifies some translational innovation gaps, and concludes with an outlook on how biomarkers and multi-omics approaches will continue to advance personalized diagnosis and therapies.
2020 08-28 SensUs Event 2020 keynote, Eindhoven, Alain van GoolAlain van Gool
Closing keynote for international students participating in the SensUs Event 2020, where they designed and created a novel sensor for drug level monitoring in epilepsy treatment. Lecture outlined innovations in biomarkers in personalized health(care).
2020 09-07 European Center Pharmaceutical Medicine course Biomarkers, Basel, ...Alain van Gool
Tutorial lecture on biomarkers for pharmaceutical industry R&D professionals, outlining status, potential and challenges of biomarkers in pharma, clinic and society.
2021 03-25 11th World Clinical Biomarkers & Companion Diagnostics, Alain van ...Alain van Gool
Closing keynote of a 3-day conference on clinical biomarkers and companion diagnostics, organised by Hanson Wade, outlining the power of omics approaches in healthcare and translation of inovations to impact.
2019 06-19 Dutch association for clinical chemistry and laboratory medicine -...Alain van Gool
Sharing my views on how X-omics biomarker analyses through next gen sequencing and mass spectrometry will change the landscape of diagnostics and clinical chemistry in the near future.
2019 10-14 2nd Int Congress on Precision Medicine, Munich, Alain van GoolAlain van Gool
Opening lecture at the 2nd International Congress on Precision Medicine in Munich, outlining progress in omics-based biomarkers for rare diseases, biomarker innovation gaps and multi-partner initiatives to bridge those gaps to applications. Also reviewed the highlights of our recently published Handbook of Biomarkers and Precision Medicine.
2021 06-14 EATRIS-Plus summer school, Alain van GoolAlain van Gool
Introductory lecture for the 100 participant summer school of the EATRIS-Plus project, outlining personalized medicine, biomarker and multi-omics strategies and use cases.
2018 11-26 KNAW-AcTI symposium Personalized Health, Amsterdam, Alain van GoolAlain van Gool
Lecture at a citizen discussion evening, reviewing the promises and (ethical) considerations of technology developments to support personalized health, organised by the Royal Academy of Sciences and the Netherlands Academy of Technology and Innovation.
ClinicalCodes.org: An online repository of clinical code lists for primary ca...David Springate
This document discusses ClinicalCodes.org, an online repository for clinical code lists used in primary care database research. It outlines issues with a lack of published code lists, such as inability to validate or replicate studies and difficulty comparing studies over time as condition definitions change. ClinicalCodes.org aims to address these issues by providing a central location for researchers to upload, download, and archive code lists. This would improve research quality and allow other researchers to build upon previous work in a standardized way. Motivations for researchers to upload their code lists include validation of their work, increased citations, and a requirement by journals and funders for transparent and accessible code lists.
2017 09-20 HUPO2017, Dublin, Alain van Gool withsupplAlain van Gool
Keynote lecture at the HUPO 2017 in Dublin, focussing on our innovations in translational omics for applications in our personalized healthcare at Radboudumc.
2018 03-01 International Conference on Perspectives in Precision Medicine, Co...Alain van Gool
This keynote lecture reviews the historical and ongoing investments in public-private partnerships related to precision medicine and the related technological infrastructures. It served as example to the Danish community how translational biomarkers in precision medicine can be organised, as basis for further collaboration between Denmark and Netherlands.
2017 02-22 Oxford Global Biomarker Congress, Manchester, Alain van GoolAlain van Gool
Outline of various technology infrastructures (in Radboudumc, Netherlands, European) aiming at filing innovation gaps in personalized medicine and health research.
Clinicians and microbiologists should follow proper procedures for collecting and handling wound swab specimens to obtain accurate microbiology results. Specimens should be collected prior to cleaning or antimicrobial treatment, using sterile collection methods. Swabs should be placed in transport media and containers sealed and transported promptly to the laboratory. Microbiologists should not receive specimens for acid-fast bacilli on swabs, as pus or tissue is preferred. Clinicians need to understand that positive cultures do not necessarily indicate infection, as opportunistic organisms may colonize wounds, and microbiology results depend on the quality of the specimen collected.
Two-thirds of survey respondents reported using a subscription video on demand (SVOD) service. Nearly half use their SVOD service as much as or more than their pay TV service. Three-quarters of SVOD users experience buffering and slow stream starts, and nearly 20% consider technical problems serious enough to cancel their service. Password sharing is common, primarily between family members, though concerns about its impact are likely overblown according to the research. Consumers expect a high-quality, premium viewing experience from SVOD services.
A empresa de tecnologia anunciou um novo smartphone com câmera aprimorada, maior tela e bateria de longa duração. O dispositivo também possui processador mais rápido e armazenamento expansível. O novo modelo será lançado em outubro por um preço inicial de US$799.
A empresa de tecnologia anunciou um novo smartphone com câmera avançada, bateria de longa duração e processador rápido para competir no mercado. O dispositivo custará menos do que os principais concorrentes e estará disponível em várias cores para atender a diferentes gostos. A empresa espera que o novo aparelho ajude a aumentar sua participação no mercado de smartphones.
A empresa de tecnologia anunciou um novo smartphone com câmera aprimorada, tela maior e bateria de longa duração por um preço acessível. O novo aparelho oferece especificações técnicas avançadas para competir com rivais e atender às necessidades dos usuários por um dispositivo completo a um preço justo.
The document proposes a magazine called "Evolution of DBZ" targeted at Dragon Ball Z fans. The core audience would be any gender interested in Dragon Ball Z willing to spend £1 on the magazine. A secondary audience would include those interested in learning about anime or seeing Dragon Ball Z as an interest. The front cover would appeal to audiences with colorful images of a DBZ character and the creator portraying a fighting pose, along with a martial arts symbol relating to DBZ and the creator. The main article would provide bright, colorful information about the newest Dragon Ball franchise iteration in an engaging style. Advertisements would use big fonts to promote related anime games and cinema systems. The total proposed annual budget is £240,000,
Improved Applications with IPv6: an overviewCisco DevNet
A session in the DevNet Zone at Cisco Live, Berlin. Deployment of IPv6 is rapidly expanding. Support for IPv6 in applications is lagging behind. Vendors such as Apple are taking steps to rectify this situation and raise awareness to the problem. The session explains why this evolution happens now, including looking at Cisco collected adoption statistics and how IPv4 address exhaustion issues affect application performance. The majority of the session focuses on how applications should adopt and support IPv6. We start with simple dual-stack IPv4/IPv6 support in applications for different operating systems to achieve functional parity with IPv4. We then discuss some of the more interesting ways of delivering applications which are only feasible with IPv6 and we explain how they can help to improve application functionality. The session includes aspects such as utilizing multiple IPv6 addresses, "happy eyeball" techniques, using different type of IPv6 addresses and more. The session will discuss existing and evolving technologies.
2015 10-06 Building Bridges Biomarker symposium FIMM Helsinki, Alain van GoolAlain van Gool
A unique honour and opportunity to give a 1.5 hour lecture to young biomarker scientists to introduce biomarkers and their importance in translational medicine and personalized healthcare.
The document discusses the convergence of traditional TV and digital video. It notes that while digital video spending and viewership has grown significantly, it still accounts for only about 10% of the total US TV and video market. Several factors are driving the convergence of traditional and digital media, including the proliferation of internet-connected devices, the rise of over-the-top streaming services, and major companies in tech and media investing heavily in original digital video content and making acquisitions in the space. The document argues that players in the TV and video ecosystem should focus on serving the entire market rather than just digital or traditional segments.
EU FP7 CarTarDis project overview April 2015Alain van Gool
The document describes CarTarDis, a 4-year public-private partnership with 13 partners from 8 countries and a budget of 8.0M Euros that began on October 1, 2013. The project aims to discover novel cardiovascular drug targets through a strong interdisciplinary team with expertise in cardiovascular disease biology, drug discovery, translational medicine, omics technologies, and more. CarTarDis will utilize unique human cohort data, biobanks, CVD models and samples to generate a candidate target database, review targets, validate a shortlist, and create online dossiers to share knowledge on selected targets. The goal is to prioritize 11 targets for further validation activities to identify new treatments for cardiovascular disease.
This short document provides instructions for creating a Haiku Deck presentation on SlideShare and being inspired. It encourages the reader to get started making their own Haiku Deck presentation by clicking a "GET STARTED" button at the bottom. The document contains photos but no other words.
2014 08-20 Radboudumc-Health Valley-LSH: Personalized Healthcare through inte...Alain van Gool
1) Personalized healthcare aims to stratify patients based on multi-level diagnoses and patient preferences to select personalized therapies.
2) Radboud University Medical Center is working to advance personalized healthcare through various technology centers that integrate omics data like genomics, glycomics, and metabolomics.
3) Key goals include developing diagnostic tests and personalized therapies through collaborative projects, working with innovators and spin-off companies, and integrating data and technologies.
The document discusses 3 steps for finding the right financial advisor: asking your current advisor to email any relevant information discussed, deciding if they are the best fit for your needs, and scheduling an in-person meeting with a potential new advisor.
2016 05-24 Kick-off The Danish Biomarker Network, Copenhagen, Alain van GoolAlain van Gool
Keynote lecture given at the kick-off of The Danish Biomarker Network in Copenhagen for a great audience of enthousiastic patients, biotech/pharma developers and ICT experts.
2019 02-21 Oxford Global 14th Biomarker Congress, Manchester, Alain van GoolAlain van Gool
1. Professor Alain van Gool presented on using clinical x-omics to drive personalized healthcare.
2. He described case studies where combining different omic approaches like genomics, metabolomics, and glycomics led to novel disease mechanisms and therapies for rare genetic diseases.
3. Van Gool advocated for increased collaboration and standardization of omic technologies to advance precision medicine and bring clinical multi-omics to higher diagnostic and therapeutic levels.
Lecture describing workflows and case studies from the Translational Metabolic Laboratory @Radboudumc how to translate x-omics biomarker signatures to clinical implementation. I also highlighted new developments to join forces in the Netherlands X-omics Initiative, United for Metabolic Disease and events/book launches in the next months.
2017 05-18 Radboudumc Information Management Inspiration Point, Nijmegen, Ala...Alain van Gool
The document discusses the validation of interleukin-8 (IL-8) as a biomarker for melanoma. A study was conducted using 59 melanoma tumor tissue samples and matching serum and plasma to validate that IL-8 is elevated in melanoma. However, the results were inconsistent, as IL-8 protein levels appeared sensitive to freeze-thawing of samples. The author advocates for increasing the quality rather than quantity of biomarker research through improved collaboration to ensure better data and validation.
2017 11-28 European Alliance for Personalised Medicine Congressm 2017, Belfas...Alain van Gool
Lecture to outline the added value of intergrating genomics with proteomics, glycomics and metabolomics to create novel personalized diagnostics and drive personalised healthcare.
2015 07-03 Nanonext NL Alain van Gool, AmsterdamAlain van Gool
The document discusses implementing personalized healthcare through measuring biomarkers. It notes that while many biomarkers have been discovered, few are validated and applied in diagnostic tests. There is also a gap in translating biomarkers into point-of-care applications. The document advocates for open innovation networks to help validate biomarkers across multiple centers and standardize clinical applications. Ultimately, the focus of personalized healthcare should be on the patient by providing individualized follow-up based on their molecular and clinical measurements.
2015 09-14 Precision Medicine 2015, London, Alain van GoolAlain van Gool
Outline of my view hoe personalized health(care) is more than just targeted medicines, also including personal motivation and actions towards disease prevention. It also outlines 4 key factors that should be in order for optimal personalized health(care): 1. start with patients first, 2. Accelerate translation research to application, 3. Copy best practice, 4. Spread the word.
2018 08-16 Masterclass Advances in Genomics Research, ErasmusMC, Rotterdam, A...Alain van Gool
Masterclass in the ErasmusMC Summerschool 'Advances in Genomics Research' for an enthousiastic group of students and professionals, talkiing about 'X-omics in Personalized Healthcare'.
2016 11-15 Lygature partnership meetup, Utrecht, Alain van GoolAlain van Gool
Contribution to the opening of the Joint Innovation Mile in the Beatrix building in Utrecht, home of the offices of Lygature, HealthRI, BBMRI-NL and others to follow.
2017 10-06 Biomarker Development Center conference, Rotterdam, Alain van GoolAlain van Gool
Lecture at the Biomarker development Center conference on biomarker validation in Rotterdam, outlining opportunities in translational biomarkers but also steps that need to be taken still.
2014 09-25 MipTec Europe's Drug Discovery eventAlain van Gool
This document discusses biomarkers in personalized healthcare and medicine. It is presented by Professor Alain van Gool, who has experience in both academia and the pharmaceutical industry researching biomarkers and personalized health. The presentation discusses the evolving role of biomarkers from diagnosis to personalized healthcare and medicine. It emphasizes the need for a systems approach using multi-omics data to develop personalized diagnostics and combination therapies for complex diseases like diabetes. Personalized healthcare is about tailoring treatment to each individual based on their molecular profiling and preferences.
2013-04-23 Top Institute Pharma Spring meeting, UtrechtAlain van Gool
Companion diagnostics use biomarkers as diagnostic tools to identify patients who will respond well to specific drug therapies. The presentation discusses the increasing use of companion diagnostics in oncology drug development and clinical trials. It provides examples of biomarkers used to identify patients with melanoma who will benefit from BRAF inhibitor drugs. While some biomarkers like BRAFV600E mutations are useful targets, tumor heterogeneity poses a challenge for companion diagnostics. The presentation calls for improving the pipeline for validating biomarkers and developing them into clinical diagnostic tests.
2018 11-28 SAB Interreg BIC project Baltic Sea Region, Copenhagen, Alain van ...Alain van Gool
Overview of the current challenges in biomarker commercialisation, to kick off the scientific advisory board meeting with the multidisciplinary Interreg BIC project team.
2015 12-09 Opening Radboud Translational Medicine, Nijmegen, Alain van GoolAlain van Gool
Keynote opening lecture at the grand opening of our new cyclotron facility, embedded in Radboud Translational Medicine and part of our Radboudumc Technology Centers. See http://www.radboudtranslationalmedicine.nl/nl/ for details.
2018 06-13 Benelux Precision Medicine Forum, Utrecht, Alain van GoolAlain van Gool
Professor Alain van Gool discusses innovations in using molecular insights for personalized health and medicine. He describes how genomics, metabolomics, glycomics, and other omics technologies can provide personalized diagnoses and therapies. Integrating these multi-omics approaches will lead to new disease mechanisms and treatments being discovered.
2019 09-23 COST CliniMARK summerschool, Spetses, Alain van GoolAlain van Gool
Opening lecture of the COST CliniMARK summer school 'Approaches for Biomarker Discovery and Validation'. Extensive introduction in biomarker approached used in pharmaceutical industry, academic research and clinical care, and society, combined with review of biomarker innovation gaps and outlook.
Similar to 2016 09-08 Copenhagen Bioscience Lecture, Alain van Gool (20)
2023-11-14 Biomarkers Europe 2023, Berlin, Alain van Gool.pdfAlain van Gool
Lecture at the Biomarkers Europe 2023 conference for an audience of pharma scientists and omics/data solution providers. I outlined several initiatives of potential interest and discussed development of our sensitive personalized clinical biomarker test for minimal residual disease monitoring in multiple myeloma.
2023-11-09 HealthRI Biobanking day_Amsterdam_Alain van Gool.pdfAlain van Gool
Examples of lessons learned in Omics-based biomarker studies from myself and colleagues in X-omics and EATRIS, for an audience of biobankers, researchers and diagnostic/clinical chemistry experts.
2023-04-20 EATRIS-Plus Summerschool, Lisbon, Alain van GoolAlain van Gool
Closing keynote lecture at the EATRIS-Plus summerschool on personalised medicine, outlining developments, opportunities, challenges and recommendations to do next in this exciting era of personalised medicine.
2022-11-23 DTL Future of data-driven life sciences, Utrecht, Alain van Gool.pdfAlain van Gool
A pitch on directions to improve experimental reproducibility, illustrated by examples of past experiences. I made the plee to move from 'Proudly invented here' to 'Proudly copyied from', to re-use each other's eperiences in successes and failures.
2022-10-12 The future of population health_Alain van Gool.pdfAlain van Gool
1) Exponential developments in omics technologies like genomics, proteomics, and metabolomics are driving more personalized approaches to healthcare.
2) Mass spectrometry methods have been developed to sensitively detect minimal residual disease in multiple myeloma patients from plasma samples, allowing for dynamic monitoring and earlier detection of relapse compared to traditional methods.
3) Large-scale multi-omics studies incorporating data from various sources can provide a more holistic view of health and disease at both the individual and population levels, supporting personalized prevention and treatment approaches.
2022-09-08 ECPM Digital Biomarkers and AI, Basel, Alain van Gool.pdfAlain van Gool
Lecture for 150 pharma professionals to outline the potentials and things-to-do with digital biomarkers, as part of a ECPM training on digitization and AI in drug development.
2022-04-14 EuroMedLab, Munich, Alain van GoolAlain van Gool
Keynote lecture at the EuroMedLab 2021 providing an audience of clinical chemists and laboratory medicine scientists with advancements of multi-omics applications in personalized healthcare, and challenges that we need to solve as translational scientists.
2021 12-10 Amalia Science Day, Nijmegen, Alain van GoolAlain van Gool
This document discusses the use of omics technologies like genomics, proteomics, and glycoproteomics in pediatric healthcare. Specifically, it describes a study that used glycoproteomics to analyze blood samples from children with febrile illness to distinguish between viral and bacterial infections. The analysis identified glycoprotein biomarkers that could accurately classify 70-80% of samples as viral or bacterial. Integrating multiple omics data through machine learning approaches may provide a more comprehensive understanding of diseases and lead to personalized diagnosis and treatment.
2019 03-14 Health Valley Event 2019, Nijmegen, Alain van GoolAlain van Gool
Lecture on innovations in personalized healthcare using an integrated X-omics approach towards personalized diagnostics, as part of the regional ambitious TopFit program.
2018 12-07 Danone-Nutricia Precision Nutrition Forum, Utrecht, Alain van GoolAlain van Gool
1. The document discusses innovations in personalized health and healthcare using various omics technologies and big data. It highlights developments in genomics, metabolomics, glycomics, and proteomics that enable personalized diagnosis and therapy.
2. Several examples are provided of how multi-omics approaches combined with whole exome sequencing can identify new disease mechanisms and biomarkers for precision medicine in genetic disorders.
3. The development of systems approaches that integrate multi-level omics data, environment, and lifestyle factors is needed to create personalized data-driven tools to monitor health and provide customized recommendations.
2018 12-04 CHAINS X-omics workshop lecture, Veldhoven, Alain van GoolAlain van Gool
Introducing the innovations we plan to do in the Netherlands X-omics Initative, together with other X-omics consortium members, at a dedicated X-omics workshop at the annual congres of the Netherlands Chemistry society.
2018 11-02 Healthy Brain Cohort progress meeting, Nijmegen, Alain van GoolAlain van Gool
Highlights and anecdotes from my experiences in interdisciplinary research in big data for personalized healthcare whilst working in Europe, USA and Singapore
TEST BANK For An Introduction to Brain and Behavior, 7th Edition by Bryan Kol...rightmanforbloodline
TEST BANK For An Introduction to Brain and Behavior, 7th Edition by Bryan Kolb, Ian Q. Whishaw, Verified Chapters 1 - 16, Complete Newest Versio
TEST BANK For An Introduction to Brain and Behavior, 7th Edition by Bryan Kolb, Ian Q. Whishaw, Verified Chapters 1 - 16, Complete Newest Version
TEST BANK For An Introduction to Brain and Behavior, 7th Edition by Bryan Kolb, Ian Q. Whishaw, Verified Chapters 1 - 16, Complete Newest Version
Clinic ^%[+27633867063*Abortion Pills For Sale In Tembisa Central19various
Clinic ^%[+27633867063*Abortion Pills For Sale In Tembisa Central Clinic ^%[+27633867063*Abortion Pills For Sale In Tembisa CentralClinic ^%[+27633867063*Abortion Pills For Sale In Tembisa CentralClinic ^%[+27633867063*Abortion Pills For Sale In Tembisa CentralClinic ^%[+27633867063*Abortion Pills For Sale In Tembisa Central
8 Surprising Reasons To Meditate 40 Minutes A Day That Can Change Your Life.pptxHolistified Wellness
We’re talking about Vedic Meditation, a form of meditation that has been around for at least 5,000 years. Back then, the people who lived in the Indus Valley, now known as India and Pakistan, practised meditation as a fundamental part of daily life. This knowledge that has given us yoga and Ayurveda, was known as Veda, hence the name Vedic. And though there are some written records, the practice has been passed down verbally from generation to generation.
Histololgy of Female Reproductive System.pptxAyeshaZaid1
Dive into an in-depth exploration of the histological structure of female reproductive system with this comprehensive lecture. Presented by Dr. Ayesha Irfan, Assistant Professor of Anatomy, this presentation covers the Gross anatomy and functional histology of the female reproductive organs. Ideal for students, educators, and anyone interested in medical science, this lecture provides clear explanations, detailed diagrams, and valuable insights into female reproductive system. Enhance your knowledge and understanding of this essential aspect of human biology.
TEST BANK For Community Health Nursing A Canadian Perspective, 5th Edition by...Donc Test
TEST BANK For Community Health Nursing A Canadian Perspective, 5th Edition by Stamler, Verified Chapters 1 - 33, Complete Newest Version Community Health Nursing A Canadian Perspective, 5th Edition by Stamler, Verified Chapters 1 - 33, Complete Newest Version Community Health Nursing A Canadian Perspective, 5th Edition by Stamler Community Health Nursing A Canadian Perspective, 5th Edition TEST BANK by Stamler Test Bank For Community Health Nursing A Canadian Perspective, 5th Edition Pdf Chapters Download Test Bank For Community Health Nursing A Canadian Perspective, 5th Edition Pdf Download Stuvia Test Bank For Community Health Nursing A Canadian Perspective, 5th Edition Study Guide Test Bank For Community Health Nursing A Canadian Perspective, 5th Edition Ebook Download Stuvia Test Bank For Community Health Nursing A Canadian Perspective, 5th Edition Questions and Answers Quizlet Test Bank For Community Health Nursing A Canadian Perspective, 5th Edition Studocu Test Bank For Community Health Nursing A Canadian Perspective, 5th Edition Quizlet Test Bank For Community Health Nursing A Canadian Perspective, 5th Edition Stuvia Community Health Nursing A Canadian Perspective, 5th Edition Pdf Chapters Download Community Health Nursing A Canadian Perspective, 5th Edition Pdf Download Course Hero Community Health Nursing A Canadian Perspective, 5th Edition Answers Quizlet Community Health Nursing A Canadian Perspective, 5th Edition Ebook Download Course hero Community Health Nursing A Canadian Perspective, 5th Edition Questions and Answers Community Health Nursing A Canadian Perspective, 5th Edition Studocu Community Health Nursing A Canadian Perspective, 5th Edition Quizlet Community Health Nursing A Canadian Perspective, 5th Edition Stuvia Community Health Nursing A Canadian Perspective, 5th Edition Test Bank Pdf Chapters Download Community Health Nursing A Canadian Perspective, 5th Edition Test Bank Pdf Download Stuvia Community Health Nursing A Canadian Perspective, 5th Edition Test Bank Study Guide Questions and Answers Community Health Nursing A Canadian Perspective, 5th Edition Test Bank Ebook Download Stuvia Community Health Nursing A Canadian Perspective, 5th Edition Test Bank Questions Quizlet Community Health Nursing A Canadian Perspective, 5th Edition Test Bank Studocu Community Health Nursing A Canadian Perspective, 5th Edition Test Bank Quizlet Community Health Nursing A Canadian Perspective, 5th Edition Test Bank Stuvia
Promoting Wellbeing - Applied Social Psychology - Psychology SuperNotesPsychoTech Services
A proprietary approach developed by bringing together the best of learning theories from Psychology, design principles from the world of visualization, and pedagogical methods from over a decade of training experience, that enables you to: Learn better, faster!
Muktapishti is a traditional Ayurvedic preparation made from Shoditha Mukta (Purified Pearl), is believed to help regulate thyroid function and reduce symptoms of hyperthyroidism due to its cooling and balancing properties. Clinical evidence on its efficacy remains limited, necessitating further research to validate its therapeutic benefits.
Cell Therapy Expansion and Challenges in Autoimmune DiseaseHealth Advances
There is increasing confidence that cell therapies will soon play a role in the treatment of autoimmune disorders, but the extent of this impact remains to be seen. Early readouts on autologous CAR-Ts in lupus are encouraging, but manufacturing and cost limitations are likely to restrict access to highly refractory patients. Allogeneic CAR-Ts have the potential to broaden access to earlier lines of treatment due to their inherent cost benefits, however they will need to demonstrate comparable or improved efficacy to established modalities.
In addition to infrastructure and capacity constraints, CAR-Ts face a very different risk-benefit dynamic in autoimmune compared to oncology, highlighting the need for tolerable therapies with low adverse event risk. CAR-NK and Treg-based therapies are also being developed in certain autoimmune disorders and may demonstrate favorable safety profiles. Several novel non-cell therapies such as bispecific antibodies, nanobodies, and RNAi drugs, may also offer future alternative competitive solutions with variable value propositions.
Widespread adoption of cell therapies will not only require strong efficacy and safety data, but also adapted pricing and access strategies. At oncology-based price points, CAR-Ts are unlikely to achieve broad market access in autoimmune disorders, with eligible patient populations that are potentially orders of magnitude greater than the number of currently addressable cancer patients. Developers have made strides towards reducing cell therapy COGS while improving manufacturing efficiency, but payors will inevitably restrict access until more sustainable pricing is achieved.
Despite these headwinds, industry leaders and investors remain confident that cell therapies are poised to address significant unmet need in patients suffering from autoimmune disorders. However, the extent of this impact on the treatment landscape remains to be seen, as the industry rapidly approaches an inflection point.
Rasamanikya is a excellent preparation in the field of Rasashastra, it is used in various Kushtha Roga, Shwasa, Vicharchika, Bhagandara, Vatarakta, and Phiranga Roga. In this article Preparation& Comparative analytical profile for both Formulationon i.e Rasamanikya prepared by Kushmanda swarasa & Churnodhaka Shodita Haratala. The study aims to provide insights into the comparative efficacy and analytical aspects of these formulations for enhanced therapeutic outcomes.
2016 09-08 Copenhagen Bioscience Lecture, Alain van Gool
1. Translating molecular biomarkers to
novel diagnostics and
impact in personalized health(care)
Prof Alain van Gool
Copenhagen Bioscience Lecture
8 September 2016
2. My path 1989-now
• Molecular biology
• Mechanisms of disease
• Biomarkers
• Omics / technologies
• Translational medicine
• Personalized healthcare
Senior Scientist Integrator Biomarkers
Scientific lead DTL-Technologies
Head EATRIS Biomarker Platform
Professor of Personalized Healthcare
Head Radboud Center for Proteomics, Glycomics & Metabolomics
Coordinator Radboud Technology Centers
2 Alain van Gool, Copenhagen Bioscience Lecture, 8 Sept 2016
4. Source: Chakma, Journal of Young Investigators, 16, 2009
Principle of Personalized Medicine
4
• The right drug for right patient at right dose at right time
• Molecular biomarkers as key drivers of patient selection
• = Precision medicine or Targeted medicine
4 Alain van Gool, Copenhagen Bioscience Lecture, 8 Sept 2016
5. Example: Personalized medicine in melanoma
B-RAFV600E mutation Strong growth of cell Growth of tumor
• B-RAFV600E cells always grow and become cancer cells
• RAF inhibitors will block pathway, block cell growth
and inhibit cancers that have a B-RAFV600E mutation
• 60% of melanoma patients have B-RAFV600E mutation
• Basis for a personalized medicine !
5 Alain van Gool, Copenhagen Bioscience Lecture, 8 Sept 2016
6. Personalized medicine in melanoma
Treat patients with
B-RAFV600E mutation Inhibit growth of cell
Patients live longerTumors disappearCells stop growing
B-RAFinhibitor
6 Alain van Gool, Copenhagen Bioscience Lecture, 8 Sept 2016
7. Emerging Personalized / Precision / Targeted Medicine
2010:
5%of drugs in pipeline had companion diagnostic biomarker test
2015:
80%
50%
7 Alain van Gool, Copenhagen Bioscience Lecture, 8 Sept 2016
8. Moving to personalized health(care)
{Source: Barabási 2007 NEJM 357; 4}
• People are more than linear pathways
• Different systems and networks
• Different risk factors
• Different preferences
8 Alain van Gool, Copenhagen Bioscience Lecture, 8 Sept 2016
9. Societal need in efficient personalized health(care)
{Source: prof Jan Kremer}
Towards cost effective care, less cure
9 Alain van Gool, Copenhagen Bioscience Lecture, 8 Sept 2016
10. Highest need in efficient personalized health(care)
It’s personal !
‘I want to stay healthy.’
‘If not, how do I get healthy?’
10 Alain van Gool, Copenhagen Bioscience Lecture, 8 Sept 2016
11. 3 key aspects of personalized health(care)
‘I want to stay healthy. If not, how do I get healthy?’
1. What to measure?
2. How much can it change?
3. What should be the follow-up for me?
11 Alain van Gool, Copenhagen Bioscience Lecture, 8 Sept 2016
12. 12 Alain van Gool, Copenhagen Bioscience Lecture, 8 Sept 2016
Translating Personalized Health(care) in society
13. We need a personalized data-driven GPS for health
• Monitor on background
• Alert when you are at risk
• Advice what to do
13 Alain van Gool, Copenhagen Bioscience Lecture, 8 Sept 2016
14. 3 key aspects of personalized health(care)
‘I want to stay healthy. If not, how do I get healthy?’
1. What to measure?
2. How much can it change?
3. What should be the follow-up for me?
14 Alain van Gool, Copenhagen Bioscience Lecture, 8 Sept 2016
15. 15 Alain van Gool, Copenhagen Bioscience Lecture, 8 Sept 2016
15
New data
(generators, owners)
16. What does my DNA tell me?
23% chance blond hair 3.1% Neanderthaler DNA
16 Alain van Gool, Copenhagen Bioscience Lecture, 8 Sept 2016
17. Genetic risk lung cancer
→ don’t smoke !
What does my DNA tell me?
No expected adverse reaction
to Warfarin
17 Alain van Gool, Copenhagen Bioscience Lecture, 8 Sept 2016
23. 23 Alain van Gool, Copenhagen Bioscience Lecture, 8 Sept 2016
Conventional or “Bottom-Up” proteomics • Single proteins
• Protein complexes
• Cells
• Tissues
• Organelles
• Membranes
• Circulating vesicles
• Body fluids
24. Example cellular proteome profiling
Sample: HEK293 whole cell proteome (1 µg tryptic digest of urea extract)
1D LC-M/MS bottom-up proteomics analysis
Retention time
m/z
400
600
800
1000
1200
1400
m/z
10 20 30 40 50 60 Time [min]
Blue: signal intensity in MS
Pink dots: precursors selected for MS/MS
Detected peaks in MS spectra 1.584.599
Detected isotope patterns in MS spectra 130.172
Total number of MS/MS spectra 22.743
Av. Absolute Mass Deviation [ppm] 2,8972
Matched MS/MS spectra 5.603
Identified NR peptides 4.537
Identified proteins 1.321
False Discovery Rate 0,98%
In 1 scan:
24 Alain van Gool, Copenhagen Bioscience Lecture, 8 Sept 2016
25. Targeted proteomics for biomarker validation
• Select potential protein biomarkers
• Select suitable peptides and fragment ions
• Develop multiplex MRM assay
• Measure (very complex) samples
Nature Methods:
Method of the year 2012
Protein A isoform 1
Protein A isoform 2
Protein B
25 Alain van Gool, Copenhagen Bioscience Lecture, 8 Sept 2016
26. Innovation in protein biomarker diagnostics
Current diagnostic protein assays:
• Mostly protein abundance
• Often unknown epitope of detection
• Ignore occurence of proteoforms
26 Alain van Gool, Copenhagen Bioscience Lecture, 8 Sept 2016
28. 28 Alain van Gool, Copenhagen Bioscience Lecture, 8 Sept 2016
Intact protein analysis
Top-down proteomics
{Hans Wessels, Alain van Gool}
29. Top-Down proteomics: characterization of protein-ligand products
Measured vs simulated spectrumChromatographic trace of Exendin-NODAGA
Annotated CID MS/MS spectrum of Exendin-NODAGA with 100% sequence coverage
29 Alain van Gool, Copenhagen Bioscience Lecture, 8 Sept 2016
30. Top-Down proteomics: analysis of in-vitro protein processing
HIS-tagremovalbyprotease
30 Alain van Gool, Copenhagen Bioscience Lecture, 8 Sept 2016
31. Top-Down proteomics: analysis of intact antibody
G0: GlcNAc2Man3GlcNAc2
G0F: GlcNAc2Man3GlcNAc2Fuc1
G1F: GalGlcNAc2Man3GlcNAc2Fuc1
G2F: Gal2GlcNAc2Man3GlcNAc2Fuc1
148.000 Da m/z !
Glycosylations
31 Alain van Gool, Copenhagen Bioscience Lecture, 8 Sept 2016
32. Top-Down proteomics: analysis of highly purified complex I
Sequence coverage of NIDM subunit
MS/MS sequence coverage: 85.7% MS sequence coverage: 100%
m/z z MASCOT Score Residues Fragmentation Modifications
841.2617 13 128 S2-K92 ETD Truncated Met, Acetyl: 1
16
29
19
7411 8860 18355 10810977 155137 17598 1406 1431411381138 13146 128 164146123 170149134 17851 120 187191
13
39
23
18 70
64
61
43
36
34
66
27 42
89
21
49 93 99 173104
7231 83 1855838 91102 1111019679 161152117474 135 168121 125 15786 167158144 1627525 18815013082 18154 177103 115
CI filtered Captive 3ul 05FA_Tray02-E1_01_1071.d
0.5
1.0
1.5
2.0
7x10
Intens.
10 20 30 40 50 Time [min]
Extracted Ion Chromatograms
NIDM subunit
Mr 10.923,3198 Da
Mass error: 0.0088Da (0.81 ppm)
• Unambiguous identification and quantitation of mature molecular forms of Complex I subunits
• 42 subunits but >250 proteoforms detected !
• Insights into the combined dynamics of all available PTMs in a single experiment
(Complex I crystal-grade purified from Yarrowia lipolytica)
32 Alain van Gool, Copenhagen Bioscience Lecture, 8 Sept 2016
{Hans Wessels, Ulrich Brandt, Alain van Gool}
33. Top-Down proteomics: analysis of isolated membrane complexes
Chromatographic separation of complex V and identification of subunit ATP5J
Ragged N-terminus of ATP5J
Nativegelelectrophoresis
33 Alain van Gool, Copenhagen Bioscience Lecture, 8 Sept 2016
{Hans Wessels, Sergio Guerrero-Castillo, Ulrich Brandt, Alain van Gool}
34. Top-Down proteomics: map subunit-PTMs in specific complexes
Different proteoforms of subunit COX5A within complex IV
Nativegelelectrophoresis
Annotation Mr (Da) Relative
occurrence
Proteoform ID
by top down
MS2?
Modification ID
by bottom-up
MS2?
N terminus ID
by bottom-up
MS2?
44-END phospho 12.509,3623 52,1 % Yes - Yes
44-END 12.429,3950 41,6 % Yes Yes
46-END phospho 12.285,2733 2,9 % - - -
43-END deamidated 12.592,4715 1,4 % - Deamidation
N77 and N102
-
43-END 12.592,4715 1,1 % - -
44-END acetyl 12.471,3661 0,5 % - Acetyl N-term
Acetyl K89
Yes
44-END acetyl+acetyl 12.513,3739 0,4% - Acetyl N-term
Acetyl K89
Yes
(Sequence 100% proteoforms identified using top down and bottom-up MS and MS/MS)
(Mass error top-down MS2 0,6-0,7 ppm)
• Accurate relative quantitation of all proteoforms of one subunit in complex IV
• Much better insight as compared to:
• Bottom-up analysis of peptide fragments alone (missing protein data)
• Analysis after enrichment for specific PTMs (eg phosphoproteomics)
34 Alain van Gool, Copenhagen Bioscience Lecture, 8 Sept 2016
35. Next: intact complexome proteins as new biomarkers?
• Native tissue biopsies
• Isolate intact membrane complexes
• Separate and isolate complexes using native gels
• LC-MS/MS analysis of intact proteins
• Data analysis
Tissue 1
(n=3)
Tissue
2 (n=3)
Subunit
Subunit – tissue 1
Subunit – tissue 2
• Identified protein sequence of subunit
• Deduce simulated sequences from database
• Determine fit with experimental data
35
{Hans Wessels, Sergio Guerrero-Castillo, Susanne Arnold, Ulrich Brandt, Alain van Gool}
36. Glycoproteomics workflow
• Mass spectrometry analysis of glycoproteins in human plasma
• 0,05 microliter analysis: detection of 1.000.000 signals in one scan (1,4 Gb)
• ~40.000 peptides of which >80% contain sugar modification
• Use to diagnose patients and identify new biomarkers
500
1000
1500
2000
m/z
5 10 15 20 25 30 35 40 Time [min]
Proof of principle study:
{Hans Wessels, Monique van Scherpenzeel, Dirk Lefeber, Alain van Gool}
Biomarkers !?
36 Alain van Gool, Copenhagen Bioscience Lecture, 8 Sept 2016
37. New diagnostic glycoprotein biomarker
• Rare metabolic disease cases (liver disease and dilated cardiomyopathy)
• Combination glycoproteomics and exome sequencing
• Identification of deficient enzyme in glycosylation pathway
• Outcome 1: Explanation of disease
• Outcome 2: Dietary intervention as succesful personalized therapy
• Outcome 3: Glyco -transferrin profile developed as diagnostic mass spec test
{Monique van Scherpenzeel, Dirk Lefeber}
37 Alain van Gool, Copenhagen Bioscience Lecture, 8 Sept 2016
38. 3 key aspects of personalized health(care)
‘I want to stay healthy. If not, how do I get healthy?’
1. What to measure?
2. How much can it change?
3. What should be the follow-up for me?
39. Personalized health(care) model
Personalized
Intervention
of patients-like-me
Personal thresholds
of persons-like-me
Big
Biomarker
Data
Molecular
Non-molecular
Environment
…
HomeostasisAllostasisDisease
Time
Disease
Health
Selfmonitoring
Adapted from Jan van der Greef, TNO
Personal profile
Personalized health
Personalized medicine
39 Alain van Gool, Radboudumc Grand Rounds, 22 Aug 2016
40. 3 key aspects of personalized health(care)
‘I want to stay healthy. If not, how do I get healthy?’
1. What to measure?
2. How much can it change?
3. What should be the follow-up for me?
40 Alain van Gool, Radboudumc Grand Rounds, 22 Aug 2016
41. 3. What should be the follow-up for me?
Personal profile data
Knowledge
Understanding
Decision
Action
41 Alain van Gool, Radboudumc Grand Rounds, 22 Aug 2016
43. Biomarker innovation gaps !
Discovery Clinical
validation/confirmation
Diagnostic
test
Number of
biomarkers
Gap 1
Gap 2
Gap 3
• Too much biomarker discovery
• Too little development to application
43 Alain van Gool, Copenhagen Bioscience Lecture, 8 Sept 2016
44. Biomarker innovation gaps: some numbers
5 biomarkers/
working day
1 biomarker/
1-3 years
1 biomarker/
3-10 years
?
Eg Biomarkers in time: Prostate cancer
May 2011: n= 2,231 biomarkers
Nov 2012: n= 6,562 biomarkers
Oct 2013: n= 8,358 biomarkers
Nov 2014: n= 10,350 biomarkers
Oct 2015: n = 11,856 biomarkers
Discovery Clinical
validation/confirmation
Diagnostic
test
Number of
biomarkers
Gap 1
Gap 2
Gap 3
44 Alain van Gool, Copenhagen Bioscience Lecture, 8 Sept 2016
45. Reasons for biomarker innovation gap
• Not one integrated pipeline of biomarker R&D
• Publication pressure towards high impact papers
• Lack of interest and funding for confirmatory biomarker studies
• Hard to organize multi-lab studies
• Biology is complex on organism level
• Data cannot be reproduced
• Publishing bias towards extreme results
• Biomarker variability
• …
{Source: John Ioannidis, JAMA 2011}
{Source: Prinz, Schlange, Asadullah, Nat Rev Drug Disc 2011}
Slide from:
Alain van Gool, Eur Commission advice, 11 Sept 2012
45 Alain van Gool, Copenhagen Bioscience Lecture, 8 Sept 2016
46. Irreproducibility of data
{Freedman et al, PLOS Biology, 2015}
{2012} {2011} {2013} {2008}{2012}
46 Alain van Gool, Copenhagen Bioscience Lecture, 8 Sept 2016
47. Categories of errors leading to irreproducibility
{Freedman et al,
PLOS Biology, 2015}
47 Alain van Gool, Copenhagen Bioscience Lecture, 8 Sept 2016
48. Add to this: bad Data Stewardship
{Wilkinson et al,
Nature Scientific Data, 2016}
80% of data is not FAIR: Findable, Accessible, Interoperable, Reusable
48 Alain van Gool, Copenhagen Bioscience Lecture, 8 Sept 2016
50. Example: validation IL-8 as biomarker for melanoma
For use in BRAF-MEK-ERK inhibitor drug development programs
Literature
{Yurkovetsky, et al. Clin Cancer Res, 2007}
50 Alain van Gool, Copenhagen Bioscience Lecture, 8 Sept 2016
51. Validation study to confirm IL-8 in melanoma
Stage 1 Stage 2 Stage 3 Stage 4
H&E staining; 20x
• 42 melanoma samples (tumor tissue + matching serum & plasma, stage I-IV, from
two independent biobanks
• Genetic analysis for BRAFV600E/D mutation in genomic DNA from tissue samples
• IL-8 mRNA analysis in tissue samples by in situ hybridisation using bDNA probes
(multiplexing with 12 ERK pathway response transcripts)
• IL-8 protein analysis in tissue samples by immunohistochemistry (in parallel with 4
other ERK pathway response proteins, Ki67, Tunnel)
• IL-8 protein analysis in matching plasma and serum by IL-8 immunoassay
(3 formats: ELISA, Luminex, Mesoscale; singleplex and multiplex)
• Statistical data analysis
{Source: Alain van Gool, MSD, unpublished data 2010}
51
Alain van Gool, Copenhagen Bioscience Lecture, 8 Sept 2016
52. Example: validation IL-8 as biomarker for melanoma
For use as efficacy biomarker in development BRAF inhibitor drugs
Literature
{Yurkovetsky, et al. Clin Cancer Res, 2007}
Own data
{Unpublished, 2010}
Cause?
(6 months, 4 fte, USD 1.000.000)
52 Alain van Gool, Copenhagen Bioscience Lecture, 8 Sept 2016
• Sample history ?
• Tumor load?
54. Way forward
Quote Freedman paper:
{Freedman et al, PLOS Biology, 2015}
54 Alain van Gool, Copenhagen Bioscience Lecture, 8 Sept 2016
55. Research Biomarkers Diagnostics
Department of Laboratory Medicine, Radboud univerity medical center
Integrated Translational Research and Diagnostic Laboratory, 250 fte, yearly budget ~ 28M euro.
Close interaction with Dept of Genetics, Pathology and Medical Microbiology
Specialities:
• Proteomics, glycomics, metabolomics
• Enzymatic assays
• Neurochemistry
• Cellulair immunotherapy
• Immunomonitoring
Areas of disease:
• Metabolic diseases
• Mitochondrial diseases
• Lysosomal /glycosylation disorders
• Neuroscience
• Nefrology
• Iron metabolism
• Pediatric oncology
• Immunodeficiency
• Transplantation
In development:
• ~500 Biomarkers
• Early and late stage
• Analytical development
• Clinical validation
Assay formats:
• Immunoassay
• Turbidicity assays
• Flow cytometry
• DNA sequencing
• Mass spectrometry
• Experimental human (-ized)
invitro and invivo models for
inflammation and
immunosuppression
Validated assays*:
• ~ 1000 assays
• 3.000.000 tests/year
Areas of application:
• Personalized healthcare
• Diagnosis
• Prognosis
• Mechanism of disease
• Mechanism of drug action
Departmental community
*CCKL accreditation/RvA/EFI
55 Alain van Gool, Copenhagen Bioscience Lecture, 8 Sept 2016
57. About 280 dedicated people working in 19 Technology Centers, ~1800 users (internal, external), ~150 consortia
www.radboudumc.nl/research/technologycenters/57
• Proteins
• Metabolites
• Drugs
• PK-PD • Preclinical
• Clinical
• Behavioural
• Preclinical
• Animal facility
• Systematic review
• Cell analysis
• Sorting
• Pediatric
• Adult
• Phase 1, 2, 3, 4
• Vaccines
• Pharmaceutics
• Cyclotron
• Radio-isotopes
• Malaria parasites
• Management
• Analysis
• Sharing
• Cloud computing
• DNA
• RNA
• Internal
• External
• Early HTA
• Evidence-
based surgery
• Field lab
• Statistics
• Biological
• Structural
• Preclinical
• Clinical
• Economic
viability
• Decision
analysis
• Experimental design
• Biostatistical advice
• Electronic Health
Records
• Transmural
translation
• Best practice
• In vivo
• Functional
diagnostics
• iPSC
• Organoids
• 3D imaging
• 3D printing
• Virtual reality
58. Regional communities
RADBOUD RESEARCH FACILITIES
58 Alain van Gool, Copenhagen Bioscience Lecture, 8 Sept 2016
Campus Radboud University
Regional Bioscience Parks
Regional Health Innovation Network
59. National communities
Funding of Large
scale Scientific
Infrastructures
(>10M euro)
Data4LifeSciences
(organising biomedical data)
59 Alain van Gool, Copenhagen Bioscience Lecture, 8 Sept 2016
National Technology Infrastructure
(from 40+ partners in DTL)
National Science Agenda
(originated from citizens)
60. European communities
@Radboudumc:
Peggy Manders
Gerhard Zielhuis
@Radboudumc:
Peter Friedl
Otto Boerman
@Radboudumc:
Otto Boerman (Head Imaging Platform)
Alain van Gool (Head Biomarker Platform)
@Radboudumc:
Arnoud van der Maas
Alain van Gool
@Radboudumc:
Saskia de Wildt
Paul Smits
60 Alain van Gool, Copenhagen Bioscience Lecture, 8 Sept 2016
61. Filling the gaps - 1
GAP 1
Public increasingly funding early development, funding gap remains
Public Funding
Private Funding
Moves away from early development
Fundamental
discovery
Early Translational
F.I.M
Phase 1 Phase 2 Phase 3
GAP 1
61 Alain van Gool, Copenhagen Bioscience Lecture, 8 Sept 2016
62. Filling the gaps - 2
GAP 2
Outputs of publicly funded projects misaligned with privately financed requirements
for further development
Public Funding
Technology push, publications
Private Funding
Product and patient focus, market pull
Fundamental
discovery
Early
Translational
F.I.M
Phase 1 Phase 2 Phase 3
GAP 2
62 Alain van Gool, Copenhagen Bioscience Lecture, 8 Sept 2016
63. Collaboration & services
Matching client needs to capacities
Experts
Product
PlatformsQA & RA
PM &
Clinical
Legal &
Ethical
compliance
Training & EducationCom & IT
Biomarkers
Group
Vaccine
Group
Tracer &
Imaging
Group
ATMP’s
Group
Small
Molecules
Group
Optimise translational
trajectory
Remove barriers to multi-
disciplinary collaborationDisease
expertise
63 Alain van Gool, Copenhagen Bioscience Lecture, 8 Sept 2016
64. Ongoing independent biomarker activities
Europe
USA
{Asadullah et al, Nature Reviews Drug Discovery, Dec 2015}
64 Alain van Gool, Copenhagen Bioscience Lecture, 8 Sept 2016
66. The Good Biomarker Practice initiative
Join forces among Europe’s major academic infrastructures + industry to:
1. Establish “Good Biomarker Practice” guidelines
- on translational research, biomarker technologies, biobanking, data stewardship.
2. Efficiently execute high quality biomarker projects
- work together in clinical validation and development of probable biomarkers.
66 Alain van Gool, Copenhagen Bioscience Lecture, 8 Sept 2016
67. Netherlands: a culture of public-private partnerships
(Centre for Translational Molecular Medicine) (Top Institute Pharma)
(BioMolecular Materials)
2006-2015
67 Alain van Gool, Copenhagen Bioscience Lecture, 8 Sept 2016
68. Emerging Health Research Infrastructure in Netherlands
68 Alain van Gool, Copenhagen Bioscience Lecture, 8 Sept 2016
70. Acknowledgements
Hans Wessels Jolein Gloerich
Roel Tans Esther Willems
Dirk Lefeber Monique van
Scherpenzeel
Leo Kluijtmans Ron Wevers
Marcel Verbeek Lucien Engelen
Jan Kremer Bas Bloem
Nathalie Bovy Paul Smits
the Radboudumc Technology Centers
and many others
www.radboudumc.nl/personalizedhealthcare
www.radboudumc.nl/research/technologycenters
www.radboudresearchfacilities.nl
alain.vangool@tno.nl
alain.vangool@radboudumc.nl
www.linkedIn.com
www.slideshare.net/alainvangool
Many collaborators and funders
Jan van der Greef Ben van Ommen
Ivana Bobeldijk Hans Princen
Lars Verschuren Marjan van Erk
Suzan Wopereis Heleen Wortelboer
Wessel Kraaij Ronald Mooi
Peter van Dijken Cyrille Krul
and many others
CarTarDis
70 Alain van Gool, Copenhagen Bioscience Lecture, 8 Sept 2016
Ruben Kok Barend Mons
Jaap Heringa Merlijn van Rijswijk
and many others
Anton Ussi Florence Bietrix
Laura Bermejo Andreas Scherer
Sulev Koks Marian Hajduch
Giovanni Migliaccio
and many others